Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,488.40
(
0.70%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.84
(
-0.87%
)
Bitcoin
81,038.87
(
0.68%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

goodJohnhunting

Send PM Follow Ignore
Followers 35
Posts 1202
Boards Moderated 1
Alias Born 08/27/2000

goodJohnhunting

Member Level

Re: jakedogman1 post# 279290

Tuesday, 11/22/2016 10:45:54 AM

Tuesday, November 22, 2016 10:45:54 AM

Post# of 347009
Jake,

Again not a scientist but please elaborate as to where this was proven...


The data mining proved that 70% of administered Bavituximab didn't bind, if we trust the 200/240 B2GP1 and 30% stat sig statement from Peregrine. The remaining cohorts scored less than placebo in the trial, if we trust what was presented at ESMO. The data mining is telling us that binding is an issue. Not me.

All the best,
John

Disclaimer: Every post, and all my views are only speculative. Do not invest money or any other resources based on these post or opinions. Best of luck and do your own due diligence!

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote